Wilson’s Disease (WD) Epidemiology Forecast 2025-2034

Wilson disease is defined as a rare inherited disorder that is characterized by the accumulation of excessive amounts of copper in the body. It is estimated that the disease affects 1 in every 30,000 people, with the usual age of presentation estimated between 4 to 40 years of age.

Wilson’s Disease (WD) Epidemiology Forecast Report Coverage

Expert Market Research's “Wilson’s Disease (WD) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of Wilson’s disease (WD). It projects the future incidence and prevalence rates of Wilson’s disease (WD) across various populations. The study covers age and type as major determinants of the Wilson’s disease (WD)-affected population. The report highlights patterns in the prevalence of Wilson’s disease (WD) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Wilson’s disease (WD) in the 8 major markets.

Regions Covered

• The United States
• EU-4 (Germany, France, Italy, Spain) and the United Kingdom
• Japan
• India

Wilson’s Disease (WD): Disease Overview

Wilson’s disease (also called hepatolenticular degeneration) causes the buildup of copper in the organs of the body, especially the brain, liver, and eyes. Wilson's disease is caused by mutations in the ATP7B gene, which codes for a protein that helps transport copper into bile for excretion. A defect in this gene prevents the copper from being eliminated from the body. Without adequate treatment, the accumulation of excessive copper can lead to organ damage and even death. Common symptoms include fatigue, swelling, uncontrolled or poorly coordinated movements, or abdominal pain.

Wilson’s Disease (WD): Treatment Overview

Treatment for Wilson's disease is focused on reducing copper levels in the body and managing symptoms. Chelation therapy (Penicillamine and Trientine) is a primary treatment approach where a chelating agent is used to remove the copper from the body through urine. Zinc acetate is commonly used as a maintenance therapy to reduce the amount of copper entering the bloodstream. Zinc therapy is recommended for asymptomatic individuals who are diagnosed early.

Epidemiology

The Wilson’s disease (WD) epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for Wilson’s disease (WD) by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Wilson’s disease (WD) and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• According to an article published in Gastroenterology (2021), the prevalence of Wilson’s disease is reported to be between 1/100,000 to 1/3 million individuals.
• The carrier frequency of Wilson’s disease is estimated to be 1 per 90 individuals. Further, it is observed that populations with an increased rate of consanguineous marriages tend to have a higher incidence of the disease.
• The global incidence of Wilson’s disease is 10 to 30 million cases, with the heterozygote carrier rate estimated to be 1 in every 100 individuals.
• Wilson disease affects both males and females equally. It can be diagnosed in children as young as 3 and adults up to 70 years of age. However, the usual age of presentation is reported between the ages of 4 and 40.

Country-wise Wilson’s Disease (WD) Epidemiology

The Wilson’s disease (WD) epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of Wilson’s disease (WD) differs between countries owing to factors such as genetic diversity which influences the incidence rates of the disease in the region, genetic screening practices and diagnostic capabilities, and cultural norms, among others. As per an article published in Scientific Reports (2024), the incidence rate is reported to be high in Italy, Israel, and other European countries. Moreover, the incidence rate has increased in Asian countries like Japan and Korea.

Country Specific Stats:

Country

Prevalence (Unit)

United States

United Kingdom

Germany

Italy

France

Spain

Japan

India

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Wilson’s disease (WD) based on several factors.
• Wilson’s Disease (WD) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India)
• The report helps to identify the patient population, and the unmet needs of Wilson’s disease (WD) are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of Wilson’s disease (WD) epidemiology in the 8 major markets?
• What will be the total number of patients with Wilson’s disease (WD) across the 8 major markets during the forecast period?
• What was the country-wise prevalence of Wilson’s disease (WD) in the 8 major markets in the historical period?
• Which country will have the highest number of Wilson’s disease (WD) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of Wilson’s disease (WD) during the forecast period of 2025-2034?
• What are the currently available treatments for Wilson’s disease (WD)?
• What are the disease risks, signs, symptoms, and unmet needs of Wilson’s disease (WD)?

Related Reports

Wilson Disease Drug Pipeline Analysis Report 2024